RxDoctor Payments Data

Geoffrey Shaw, MD

Psychiatry · Northfield, ILNPI 1184730053

Payments from drug & device makers

$5,908in general payments, 2019–2025

Across 234 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$924
  • Neurocrine Biosciences, Inc.$652
  • Biogen$582
  • Novartis$411
  • AbbVie$368
  • Lilly USA, LLC$308
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$5,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,908 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$72,402
Medicare patients
99
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$29,529
Bupropion XlBupropion Hcl168$2,867
Fluoxetine Hcl303$2,656
Alprazolam175$2,483
Clonazepam153$2,140
Duloxetine Hcl144$2,053
Quetiapine Fumarate68$1,503
Methylphenidate Hcl25$1,036
Sertraline Hcl135$932
Escitalopram Oxalate42$854
Zolpidem Tartrate86$766
Lorazepam92$758
Paroxetine Hcl47$555
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$481
Divalproex Sodium ErDivalproex Sodium13$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$124$29,52915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Northfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →